Kathleen A. Day

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

Michael Ament, Kathleen A. Day, Virginia L. Stauffer et al. · The Journal of Headache and Pain · 2021 · 41 citations · Full text

Prevalence and determinants of white coat effect in a large UK hypertension clinic population

O Thomas, Kate E. Shipman, Kathleen A. Day et al. · Journal of Human Hypertension · 2015 · 35 citations

Hypertension, Blood Pressure, Cardiovascular Disease +6

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies

Noah Rosen, Eric Pearlman, Dustin Ruff et al. · Headache The Journal of Head and Face Pain · 2018 · 33 citations · Full text

Profile of Sexual and Genitourinary Treatment-Emergent Adverse Events Associated with Atomoxetine Treatment: A Pooled Analysis

Angelo Camporeale, Kathleen A. Day, Dustin Ruff et al. · Drug Safety · 2013 · 25 citations

Sexual Health, Psychiatry, Clinical Epidemiology +9

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

Virginia L. Stauffer, Ira Turner, Phebe Kemmer et al. · The Journal of Headache and Pain · 2020 · 17 citations · Full text